IDEXX Laboratories stock trades near record levels as companion animal diagnostics drive growth

IDEXX Laboratories stock remains supported by strong companion animal diagnostics demand and expanding margins, with investors watching revenue growth and valuation after recent highs.

IDEXX Laboratories stock is trading near record levels as investors continue to price in robust growth in companion animal diagnostics and software services for veterinary practices. The Maine based diagnostics specialist (ISIN US45168D1046) has seen its market capitalization rise above $40 billion in recent periods as of 16 July 2026, reflecting sustained revenue expansion and margin improvement in its latest annual and quarterly results.

Revenue up double digits in recent fiscal year

In the most recent completed fiscal year, IDEXX Laboratories reported that total revenue increased by around 12% year on year to approximately $3.0 billion, according to its latest annual filings and investor presentations in 2025. This compared with revenue of roughly $2.7 billion in the prior fiscal year, underscoring continued demand across companion animal, livestock, and water testing segments. The company indicated that companion animal group revenue, which accounts for the majority of sales, grew at a low to mid teens percentage rate, driven by higher test volumes and broader adoption of in clinic analyzers and cloud based practice management software.

Operating profitability also improved. IDEXX Laboratories reported operating income of around $900 million for the same fiscal year, up from roughly $780 million a year earlier, implying operating margin expansion of about 100 basis points to approximately 30%. Management highlighted disciplined expense control and favorable product mix, with higher margin recurring diagnostic consumables and software subscription revenue increasing as a share of the overall portfolio. Net income for the year was approximately $750 million versus about $650 million in the prior year, translating into earnings per share in the mid $8 range, up from the mid $7 range previously.

Companion animal diagnostics growth supports valuation

The company’s companion animal group remains its largest and fastest growing segment by revenue. In recent quarterly reporting for 2026, IDEXX Laboratories indicated that companion animal diagnostics and services revenue rose by around 13% compared with the same quarter a year earlier, reaching approximately $750 million for that quarter versus around $660 million previously. This growth was supported by increased veterinary clinic utilization of IDEXX’s analyzers, higher testing per visit, and expanding installed base of practice management software platforms such as Cornerstone and Neo.

Recurring revenue streams are central to the investment case. IDEXX Laboratories has emphasized that recurring diagnostics and software services account for more than 85% of total revenue, providing visibility and resilience. In fiscal 2025, recurring revenue grew by roughly 13% year on year, while instrument placements grew in the high single digits, creating future consumables and services demand. This combination of recurring revenue growth and expanding margins has helped justify a premium valuation multiple relative to broader diagnostics and animal health peers, with the stock historically trading at a forward price to earnings multiple above 40 times based on recent consensus estimates.

Margin expansion and cash flow generation

Margin trends have been a focus for investors in IDEXX Laboratories stock. In its latest annual and subsequent quarterly updates, the company reported gross margin of roughly 60% in fiscal 2025, up from about 59% the prior year, driven by scale benefits, productivity initiatives, and a higher mix of software and services. Operating margin, as noted, was around 30%, with management reiterating a long term objective of sustaining or modestly expanding margins through efficiency programs and innovation.

Free cash flow generation has also been strong. In fiscal 2025, IDEXX Laboratories generated free cash flow of approximately $650 million, compared with around $560 million in fiscal 2024, an increase of roughly 16%. Capital expenditures remained focused on laboratory capacity, R&D, and digital platforms, while the company maintained a modest dividend policy and share repurchase activity. Net leverage has been kept within a prudent range, with net debt to EBITDA around 1.0 times in recent reporting, leaving flexibility for continued investment and selective acquisitions.

Diagnostic instruments and cloud software

A major part of IDEXX Laboratories’ business model is the sale and placement of diagnostic instruments in veterinary clinics, coupled with ongoing consumables and software revenue. The company’s analyzers perform chemistry, hematology, and immunodiagnostic tests for companion animals. In recent financial reporting, IDEXX Laboratories noted that the installed base of premium analyzers increased by several thousand units in fiscal 2025, contributing to higher recurring consumables revenue in subsequent periods.

Cloud based practice management platforms complement diagnostics by integrating patient records, billing, scheduling, and laboratory results. IDEXX Laboratories has continued to invest in enhancements, highlighting growth in subscription revenue linked to these software offerings. In fiscal 2025, software and services revenue within the companion animal group grew by low double digit percentages, supporting overall segment growth and margin improvement.

Shares near yearly high level

On Nasdaq, IDEXX Laboratories stock has recently traded close to its 52 week high. As of 16 July 2026, the shares were changing hands at approximately $560, compared with a 52 week low near $430, implying a range of roughly 30% between the low and high over the past year. This price level places the market capitalization above $40 billion, with investors factoring in sustained double digit revenue growth and strong free cash flow.

Relative to broader indices such as the S&P 500, IDEXX Laboratories has delivered strong long term performance, driven by structural trends in pet ownership, increasing veterinary care utilization, and expanding test menus. The premium valuation, however, means that continued execution on growth and margin objectives remains important for supporting the share price. For investors, metrics such as revenue growth in the companion animal group, margin expansion, and recurring revenue share are key indicators to watch alongside broader market conditions.

Companion animal analyzers and test menu

Within its product portfolio, a representative offering is IDEXX’s in clinic diagnostic analyzer line, which enables veterinarians to perform blood chemistry and hematology tests quickly at the point of care. These instruments are typically sold with accompanying consumables and connected to cloud based software that manages results and integrates with practice management systems. The breadth of the test menu, covering common conditions in dogs and cats, supports higher utilization and recurring revenue over time.

IDEXX Laboratories stock price and market context

IDEXX Laboratories stock most recently closed around $560 on Nasdaq as of 16 July 2026, reflecting investor confidence in the company’s growth trajectory and margin profile. At this price, and with a market capitalization exceeding $40 billion, the shares trade at a premium valuation relative to many broader diagnostics and animal health peers, anchored by recurring revenue strength and structural demand drivers in companion animal health.

IDEXX Laboratories key facts

• Company: IDEXX Laboratories Inc.
• ISIN: US45168D1046
• Ticker: NASDAQ: IDXX
• Trading venue: Nasdaq
• Price (as of 16 July 2026, 16:00 ET): 560 USD
• Market capitalization: 40,000,000,000 USD (as of 16 July 2026)
• Sector / Industry: Health Care / Diagnostics and Veterinary Services
• Index membership: S&P 500